Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 16/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.65 |
| ▸ | CDK1 | P06493 | 2/20 | 0.65 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.65 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.65 |
| ▸ | GSK3A | P49840 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.65 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.65 |
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064965 | 1.00 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL3009852 | 0.85 | RIPK1 (0.74) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2995238 | 0.84 | RIPK1 (0.73) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL3006162 | 0.84 | RIPK1 (0.73) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL3004549 | 0.82 | RIPK1 (0.69) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL28277239 | 0.81 | RIPK1 (0.68) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL29460546 | 0.79 | RIPK1 (0.65) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL30694450 | 0.78 | RIPK1 (0.64) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL29625211 | 0.78 | RIPK1 (0.64) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31064968 | 0.78 | RIPK1 (0.63) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114149428-A | Pyridine-fused ring compound and preparation method, intermediate, composition and application thereof | 中国药科大学 | 2022-03-08 | — | — | CN | disclosed |
| EP-3362449-A1 | SIBIRILINE DERIVATIVES FOR USE FOR PREVENTING AND/OR TREATING DISORDERS ASSOCIATED WITH CELLULAR NECROPTOSIS | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017064217-A1 | SIBIRILINE DERIVATIVES FOR USE FOR PREVENTING AND/OR TREATING DISORDERS ASSOCIATED WITH CELLULAR NECROPTOSIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-04-20 | — | — | WO | disclosed |
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| CN-101563337-A | Indole compounds | MICROBIA INC (US) | 2009-10-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | RIPK1 1213/4885CCNB2 1957/4885CDK1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.